Table 1.
Idelalisib+rituximab | ||
---|---|---|
CK-positive, N = 26 | CK-negative, N = 37 | |
ORR, n (%)a | 21 (80.8) | 33 (89.2) |
95% CIb | 60.6, 93.4 | 74.6, 97.0 |
Complete response | 0 | 0 |
Partial response | 21 (80.8) | 33 (89.2) |
Stable disease | 3 (11.5) | 2 (5.4) |
Progressive disease | 1 (3.8) | 0 |
Not evaluable | 1 (3.8) | 2 (5.4) |
Odds ratio for ORRc | 0.5 | |
95% CI for odds ratio | 0.1, 2.1 | |
p-value | 0.3509 |
CI confidence interval, CK complex karyotype, IRC Independent Review Committee, ORR overall response rate
aORR is the percentage of patients who had best overall response of complete response or partial response
b95% CI for ORR is based on the exact method
cOdds ratio and 95% CI are calculated without any adjustment